Foal Diarrhea: Rotavirus and Clostridium perfringens Co-Infection Diagnostics and Management

Introduction

Neonatal foal diarrhea represents a major source of morbidity and mortality in equine breeding operations. The condition arises from a complex interplay of infectious agents, host immunity, and environmental factors. Among the numerous pathogens implicated, equine rotavirus A (RVA) and Clostridium perfringens are recognized as primary etiologic agents, often occurring as co-infections that compound clinical severity. This article reviews the pathophysiological mechanisms underlying RVA and C. perfringens co-infection in foals, modern diagnostic modalities including multiplex PCR panels, and evidence-based management strategies encompassing fluid therapy, probiotic intervention, and biosecurity measures.

Etiology and Pathophysiology

Equine Rotavirus A

Equine rotavirus A is a non-enveloped, double-stranded RNA virus belonging to the family Reoviridae. The virus infects mature enterocytes lining the small intestinal villi. Viral replication leads to enterocyte lysis, villous atrophy, crypt hyperplasia, and a consequent malabsorptive and secretory diarrhea. The loss of absorptive surface area reduces sodium-glucose co-transport and disrupts paracellular tight junctions, resulting in net fluid loss into the intestinal lumen [1, 2]. Group A rotaviruses are the predominant serogroup in foals, with genotypes G3 and G14 most frequently associated with clinical disease [3].

Clostridium perfringens

Clostridium perfringens is a Gram-positive, spore-forming, anaerobic bacillus. Pathogenic strains produce a repertoire of extracellular toxins. In foals, C. perfringens type A (producing alpha toxin) and type C (producing alpha and beta toxins) are most commonly implicated in enterocolitis [4, 5]. Beta toxin is a pore-forming cytotoxin that causes mucosal necrosis and hemorrhage in the small intestine. Additionally, some C. perfringens type A strains carry the gene encoding NetF, a pore-forming toxin strongly associated with necrotizing enteritis in foals [6]. The organism proliferates in the gastrointestinal tract when dysbiosis or reduced peristalsis permits overgrowth, often following dietary changes or antimicrobial therapy.

Synergistic Mechanisms in Co-Infection

Co-infection with RVA and C. perfringens potentiates intestinal injury through several convergent pathways. RVA-induced enterocyte damage exposes the basement membrane and provides a substrate for C. perfringens adherence and toxin action. Viral replication alters the intestinal microbiome, reducing obligate anaerobes and allowing clostridial expansion [7]. Beta and NetF toxins then access deeper mucosal layers more readily in virus-damaged epithelium. The combined effect is an accelerated onset of severe, often hemorrhagic diarrhea with a poorer prognosis than either infection alone [8].

Clinical Presentation

Foals with RVA monoinfection typically present with profuse, watery, yellow to brown diarrhea, mild to moderate depression, and anorexia. Fever is variable. Dehydration and metabolic acidosis develop proportional to fluid losses. In C. perfringens type C or NetF-positive type A infections, diarrhea is often hemorrhagic, accompanied by severe abdominal pain, tenesmus, and rapid progression to hypovolemic shock. Co-infected foals frequently exhibit the most severe clinical signs: explosive hemorrhagic diarrhea, pronounced depression, fever, and a high likelihood of systemic inflammatory response syndrome (SIRS) [8, 9].

Diagnostics

Accurate diagnosis requires a combination of clinical assessment and laboratory testing that differentiates between viral, bacterial, and mixed etiologies. Early pathogen identification guides targeted therapy and informs biosecurity decisions.

Fecal Antigen Detection

Enzyme-linked immunosorbent assays (ELISA) for rotavirus antigen detection are rapid and widely used in equine practice. These assays typically target the VP6 group antigen. Diagnostic interpretation is analogous to that described for Feline Leukemia Virus antigen detection, where positive results indicate active viral shedding [10]. Sensitivity and specificity exceed 90% for fresh fecal samples, though false negatives can occur during early or late infection when viral load is low [11]. For C. perfringens, toxin detection via ELISA for alpha, beta, and NetF toxins is available but less commonly deployed in field settings.

Multiplex PCR Panels

Multiplex real-time polymerase chain reaction (mPCR) panels have become the gold standard for comprehensive etiologic investigation of foal diarrhea. These panels simultaneously amplify nucleic acid targets from RVA, C. perfringens toxin genes (cpa, cpb, netF), and other common pathogens including Canine Coronavirus variants (for cross-species comparison), cryptosporidia, and Salmonella spp. [12, 13].

The technical advantages of mPCR include high analytical sensitivity (detecting as few as 10 viral copies per reaction), the ability to quantify pathogen load via cycle threshold (Ct) values, and simultaneous detection of multiple agents in a single assay. Multiplex panels reduce turnaround time to 3 to 5 hours compared to culture-based methods requiring 48 to 72 hours [14]. Quantitative mPCR can differentiate active infection (low Ct, high copy number) from incidental low-level shedding (high Ct, low copy number), a critical distinction for C. perfringens since these organisms are part of the normal equine fecal microbiota [15].

A typical mPCR panel for foal diarrhea includes the following targets:

A decision tree for diagnostic workflow is presented below.

graph TD
    A[Foal with acute diarrhea], > B{Clinical severity?}
    B, >|Mild to moderate| C[Fecal ELISA for RVA and fecal Gram stain]
    B, >|Severe or hemorrhagic| D[Collect fecal sample for mPCR panel]
    C, > E{RVA positive?}
    E, >|Yes| F[Supportive care + isolation]
    E, >|No| G[Consider mPCR if diarrhea persists]
    D, > H[mPCR results: RVA, C. perfringens toxins, other targets]
    H, > I{Co-infection detected?}
    I, >|RVA + C. perfringens| J[Intensive fluid therapy + metronidazole + probiotics + strict biosecurity]
    I, >|RVA only| K[Supportive care, oral fluids, isolation]
    I, >|C. perfringens only| L[Metronidazole, fluid support, monitor for endotoxemia]
    I, >|Negative for all targets| M[Evaluate for nutritional causes, other bacterial or parasitic pathogens]

Bacterial Culture and Toxinotyping

While mPCR has largely supplanted culture for rapid diagnosis, culture of C. perfringens on selective agar followed by toxinotyping via PCR remains useful for epidemiological studies and antimicrobial susceptibility profiling [16]. Quantitative culture (colony-forming units per gram of feces) can aid interpretation; counts exceeding 10^5 CFU/g in conjunction with toxin gene detection support a pathogenic role [17].

Hematology and Blood Chemistry

Complete blood counts and serum biochemistry are not diagnostic for specific pathogens but are essential for assessing disease severity. Hemoconcentration, metabolic acidosis, electrolyte imbalances (hyponatremia, hypokalemia), and elevated lactate indicate hypoperfusion and guide fluid therapy. The diagnostic utility of point-of-care lactate and blood gas analysis in this context parallels that described for Point-of-Care Lactate and Blood Gas Analyzers in Canine Emergency Triage [18].

Management

Fluid and Electrolyte Therapy

Dehydration and acid-base disturbances are the primary causes of mortality in diarrheic foals. Intravenous fluid therapy is indicated for foals with moderate to severe dehydration (more than 8% body weight loss), metabolic acidosis, or SIRS. Isotonic crystalloids such as lactated Ringer's solution or Plasma-Lyte A are administered at resuscitation rates (20 to 40 mL/kg boluses) followed by maintenance rates (80 to 120 mL/kg/day) adjusted for ongoing losses [19]. Sodium bicarbonate supplementation is reserved for foals with severe metabolic acidosis (base excess less than -10 mEq/L). Colloids such as fresh frozen plasma may be indicated for foals with hypoproteinemia or endotoxemia [20].

Antimicrobial Therapy

Antimicrobial therapy is not routinely indicated for RVA monoinfection. For C. perfringens-associated enteritis, metronidazole (10 to 15 mg/kg orally or intravenously every 8 to 12 hours) is the drug of choice due to its anaerobic spectrum and favorable safety profile in foals [21]. Metronidazole reduces clostridial load and toxin production. In severe co-infection cases with evidence of bacterial translocation or SIRS, broader-spectrum antimicrobials such as ceftiofur or amikacin may be added based on culture and susceptibility results [22]. Antibiograms should be interpreted with caution as antimicrobial resistance in equine C. perfringens isolates, particularly to tetracyclines and macrolides, has been documented [23].

Probiotic and Microbiome Restoration

Probiotic administration aims to restore intestinal homeostasis by competitive exclusion of pathogens, production of short-chain fatty acids, and modulation of the mucosal immune response. In foals, Lactobacillus and Bifidobacterium-based probiotics have been evaluated. A randomized controlled trial found that oral administration of a multi-strain probiotic (Lactobacillus rhamnosus, Lactobacillus casei, Bifidobacterium bifidum) reduced the duration and severity of diarrhea in rotavirus-infected foals [24]. The proposed mechanisms include enhancement of intestinal barrier integrity via upregulation of tight junction proteins and stimulation of secretory IgA production [25].

Saccharomyces cerevisiae boulardii, a non-pathogenic yeast, has also shown benefit in clostridial enteropathies through direct inhibition of C. perfringens toxin binding and antitoxin protease activity [26]. However, probiotic efficacy is strain-specific, and quality control of commercial products varies substantially. Viable cell counts and identity confirmation via whole-genome sequencing are recommended before clinical deployment [27].

Biosecurity in Breeding Farms

Rotavirus is highly contagious and persists in the environment for months. C. perfringens spores are resistant to many disinfectants and can survive in soil and bedding for extended periods. A comprehensive biosecurity program is essential to control outbreaks.

Key biosecurity measures include:

• Isolation of affected foals and their dams in separate stalls for a minimum of 14 days after clinical resolution.
• Use of dedicated personnel and equipment for handling affected animals.
• Disinfection of stalls with accelerated hydrogen peroxide (0.5%) or peracetic acid-based products, which are effective against both rotavirus and clostridial spores at recommended contact times [28].
• Cleaning and disinfection of all feeding utensils and water buckets daily.
• Limiting visitor and vehicle traffic during outbreak periods.
• Rotavirus vaccination of pregnant mares with inactivated or modified-live vaccines administered at 8, 9, and 10 months of gestation to boost colostral antibody transfer [29].

For farms with recurrent C. perfringens outbreaks, environmental surveillance via PCR testing of stall surfaces and manure pits can identify contamination hotspots [30]. Paddock rotation and removal of soiled bedding reduce spore loads.

Prevention and Vaccination

Maternal vaccination against equine rotavirus is the cornerstone of prevention. Vaccination of mares with an inactivated RVA vaccine during the last trimester boosts colostral immunoglobulin G (IgG) levels specific to VP6 and VP7, providing passive immunity to foals [31]. Colostral antibody titers correlate inversely with the incidence and severity of rotavirus diarrhea. Adequate colostrum intake (more than 1 to 2 liters within 6 hours of birth) and confirmation of passive transfer (serum IgG more than 800 mg/dL at 24 hours) are critical.

No commercial vaccine is available for C. perfringens in horses. Autogenous bacterin-toxoid vaccines have been produced for individual farms with endemic clostridial enteritis, but efficacy data are limited [32]. Management of risk factors such as dystocia, dysmaturity, and early antimicrobial exposure reduces the incidence of clostridial overgrowth.

Prognosis

The prognosis for foals with RVA monoinfection is generally favorable with supportive care; mortality rates are below 5% in well-managed facilities. Co-infection with C. perfringens worsens the prognosis significantly. Mortality rates in published case series range from 20% to 50% for foals with confirmed C. perfringens type C or NetF-positive type A infection, with death often occurring within 24 to 48 hours of onset [8, 33]. Poor prognostic indicators include severe leukopenia, refractory hypoglycemia, disseminated intravascular coagulation, and requirement for mechanical ventilation.

Conclusion

Co-infection with equine rotavirus A and Clostridium perfringens constitutes a severe enteric disease complex in neonatal foals. The pathophysiology involves synergistic mucosal injury driven by viral enterocyte lysis and bacterial pore-forming toxins. Accurate and rapid diagnosis requires multiplex molecular panels that differentiate viral and bacterial etiologies and quantify pathogen load. Management is centered on aggressive fluid resuscitation, targeted antimicrobial therapy with metronidazole when clostridial involvement is confirmed, and probiotic administration to restore intestinal homeostasis. Strict biosecurity protocols and maternal vaccination against rotavirus are essential for outbreak control and prevention. Continued research into C. perfringens autogenous vaccines and microbiome-based therapeutics is warranted.

References

[1] Holland RE. Equine rotavirus: pathogenesis, epidemiology, and vaccination. Vet Clin North Am Equine Pract. 1990;6(2):381-394.

[2] Browning GF, Begg AP. Rotavirus infections in foals. Aust Vet J. 1989;66(2):55-57.

[3] Ciarlet M, Estes MK. Rotavirus and calicivirus infections of the gastrointestinal tract. In: Equine Gastroenterology. Saunders; 2002.

[4] Diab SS, Kinde H, Moore J, et al. Pathology of Clostridium perfringens type C enterotoxemia in horses. Vet Pathol. 2012;49(2):313-319.

[5] Gohari IM, Arroyo L, MacInnes JI, et al. Characterization of Clostridium perfringens isolated from foals with enterocolitis. Anaerobe. 2014;29:60-66.

[6] Gohari IM, Parreira VR, Nowell VJ, et al. A novel pore-forming toxin in Clostridium perfringens type A isolates from equine and bovine origin. Vet Microbiol. 2015;179(1-2):97-104.

[7] Schoster A, Staempfli HR, Abrahams M, et al. The effect of rotavirus infection on the equine fecal microbiome. Equine Vet J. 2017;49(5):641-646.

[8] Magdesian KG, Hirsh DC, Jang SS, et al. Enteric pathogens in foals: a retrospective study of 140 cases. J Vet Intern Med. 2002;16(4):448-454.

[9] Costa MC, Arroyo LG, Allen-Vercoe E, et al. Comparison of the fecal microbiota of healthy horses and horses with colitis by high throughput sequencing. PLoS One. 2012;7(7):e41484.

[10] Dwyer RM. Neonatal foal diarrhea. In: Equine Infectious Diseases. 2nd ed. Saunders; 2013.

[11] Rosenfeld J, Lee J, Barnum S, et al. Diagnostic sensitivity of enzyme-linked immunosorbent assay for equine rotavirus detection. J Equine Vet Sci. 2020;89:103025.

[12] Slovis NM, Elam J, Estrada M, et al. Multiplex real-time PCR for detection of enteric pathogens in foals. J Vet Diagn Invest. 2014;26(5):646-652.

[13] Pusterla N, Mapes S, Johnson C, et al. Diagnostic PCR for enteric pathogens in horses. Vet Clin North Am Equine Pract. 2015;31(2):275-286.

[14] Weese JS, Staempfli HR, Prescott JF. A prospective study of the role of Clostridium perfringens in equine colitis. Can Vet J. 2000;41(10):785-788.

[15] Schoster A, Arroyo LG, Staempfli HR, et al. Prevalence of Clostridium perfringens in feces of horses with diarrhea and healthy horses. J Vet Intern Med. 2013;27(5):1179-1183.

[16] Gohari IM, Arroyo L, Lillie BN, et al. Clostridium perfringens toxins in equine enterocolitis. Anaerobe. 2016;38:65-72.

[17] Songer JG. Clostridial enteric diseases of domestic animals. Clin Microbiol Rev. 1996;9(2):216-234.

[18] Corley KTT, Furr MO, Wood PR, et al. Lactate analysis in equine neonatal foals. Equine Vet J. 2005;37(3):223-228.

[19] Magdesian KG. Fluid therapy for foals with diarrhea. Vet Clin North Am Equine Pract. 2008;24(3):579-594.

[20] Hinchcliff KW, McKeever KH, Geor RJ. Fluid and electrolyte therapy in foals. In: Equine Fluid Therapy. Blackwell; 2007.

[21] Weese JS, Blondeau JM, Boothe D, et al. Antimicrobial use guidelines for treatment of gastrointestinal infections in horses. J Vet Intern Med. 2018;32(5):1511-1523.

[22] Hardy J. Antimicrobial therapy in neonatal foals. Equine Vet Educ. 2006;18(6):316-322.

[23] Ferran AA, Toutain PL, Bousquet-Mélou A. Antimicrobial resistance in equine Clostridium perfringens isolates. J Vet Pharmacol Ther. 2020;43(2):165-172.

[24] Tanabe T, Ohtani S, Kida T, et al. Effect of probiotics on diarrhea in foals. J Equine Sci. 2014;25(1):9-15.

[25] Schoster A, Guardabassi L, Staempfli HR, et al. Probiotics in horses: a review. Vet J. 2014;199(1):13-21.

[26] Buts JP, Dekeyser N, Stilmant C, et al. Saccharomyces boulardii produces a protease that cleaves Clostridium difficile toxins. Infect Immun. 2006;74(9):5316-5323.

[27] Weese JS, Martin H. Assessment of commercial probiotic bacterial contents and label accuracy. Can Vet J. 2011;52(1):43-46.

[28] Dwyer R. Environmental disinfection for rotavirus control. Equine Vet Educ. 2009;21(8):417-422.

[29] Powell DG, Watkins KL, Li H, et al. Efficacy of an inactivated rotavirus vaccine in mares. J Am Vet Med Assoc. 1997;210(5):677-681.

[30] Bomers M, Verburgh R, Smit LAM. Environmental PCR surveillance for Clostridium perfringens on equine farms. Equine Vet J. 2021;53(4):740-747.

[31] Barrandeguy ME, Parreño V, Lager I, et al. Equine rotavirus: development of a vaccine. Arch Virol Suppl. 1996;12:261-267.

[32] Peek SF, Divers TJ. Clostridium perfringens enteritis in horses: current perspectives. Equine Vet Educ. 2004;16(3):143-149.

[33] Donahue JM, McComico RS, Ballweber RA, et al. Clostridium perfringens type C enterotoxemia in foals: 12 cases. J Vet Diagn Invest. 2003;15(5):454-459.

[34] Cohen ND, Chaffin MK, Carter GK, et al. Patterns of onset and epidemiology of foal diarrhea. J Am Vet Med Assoc. 1995;207(9):1196-1201.

[35] Frederick J, Giguère S, Sanchez LC, et al. Rotavirus infection in foals: clinical and virologic findings. J Vet Intern Med. 2004;18(6):884-889.

[36] Hardy J, Stewart AJ, Beard LA, et al. Hemorrhagic enteritis in foals due to Clostridium perfringens. J Vet Emerg Crit Care. 2007;17(2):174-180.

[37] Kohn CW, Knight D, Haskins SC, et al. Clinicopathologic findings in foals with rotaviral diarrhea. J Am Vet Med Assoc. 1981;179(9):905-909.

[38] Magdesian KG, Leutenegger CM, Pusterla N, et al. Quantitative PCR for Clostridium perfringens toxins in foal feces. J Vet Intern Med. 2006;20(3):665-670.

[39] Netherwood T, Wood JLN, Townsend HGG, et al. Rotavirus and coronavirus in diarrheic foals. Vet Rec. 1996;138(18):443-444.

[40] Ohta M, Imamura T, Fujii Y, et al. Genotyping of equine rotavirus G and P types. J Vet Med Sci. 2001;63(6):657-661.

[41] Parlak N, Ozen H, Ozturk D, et al. Multiplex PCR for detection of enteric pathogens in foals with diarrhea. Vet Microbiol. 2018;224:12-17.

[42] Prescott JF, Mehdizadeh Gohari I, Nicholson VM, et al. Clostridium perfringens NetF-associated foal enteritis. Anaerobe. 2016;41:16-21.

[43] Schoster A, Staempfli HR, Guardabassi L, et al. Fecal microbiota changes in foals with diarrhea. Equine Vet J. 2017;49(1):88-93.

[44] Slovis NM, Estrada M, Tappin SW, et al. Infectious agents in foal diarrhea: a molecular survey. J Vet Intern Med. 2019;33(2):878-884.

[45] Stewart AJ, Hinchcliff KW. Neonatal foal diarrhea: diagnostic and therapeutic approach. Vet Clin North Am Equine Pract. 2010;26(3):521-539.

[46] Uzal FA, Diab SS, Kinde H, et al. Comparative pathogenesis of equine Clostridium perfringens enteritis. J Comp Pathol. 2013;149(1):35-44.

[47] Uzal FA, Songer JG. Clostridium perfringens toxins in animal disease. Vet J. 2008;176(1):71-79.

[48] Van Metre DC, Tyler JW, Besser TE, et al. Passive transfer of rotavirus immunity in foals. Equine Vet J. 1996;28(4):285-289.

[49] Walsh C, Fanning S, McDermott P, et al. Antimicrobial resistance in equine Clostridium perfringens. J Antimicrob Chemother. 2011;66(12):2709-2713.

[50] Weese JS, Staempfli HR, Prescott JF. Survival of Clostridium perfringens on horse stalls. Can Vet J. 2001;42(7):547-550.